235 related articles for article (PubMed ID: 22057683)
21. Effects of immunoglobulin plus prednisolone in reducing coronary artery lesions in patients with Kawasaki disease: study protocol for a phase III multicenter, open-label, blinded-endpoints randomized controlled trial.
Lin SY; He L; Xie LP; Wang Y; Lin YX; Cao YY; Yan WL; Liu F; Huang GY
Trials; 2021 Dec; 22(1):898. PubMed ID: 34895290
[TBL] [Abstract][Full Text] [Related]
22. Revisiting the role of steroids and aspirin in the management of acute Kawasaki disease.
Dhanrajani A; Yeung RSM
Curr Opin Rheumatol; 2017 Sep; 29(5):547-552. PubMed ID: 28661936
[TBL] [Abstract][Full Text] [Related]
23. Epidemiologic study of Kawasaki disease and cases resistant to IVIG therapy in Thailand.
Durongpisitkul K; Sangtawesin C; Khongphatthanayopthin A; Panamonta M; Sopontammarak S; Sittiwangkul R; Pongpanich B
Asian Pac J Allergy Immunol; 2006 Mar; 24(1):27-32. PubMed ID: 16913186
[TBL] [Abstract][Full Text] [Related]
24. Management of Kawasaki disease.
Eleftheriou D; Levin M; Shingadia D; Tulloh R; Klein NJ; Brogan PA
Arch Dis Child; 2014 Jan; 99(1):74-83. PubMed ID: 24162006
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of intravenous immunoglobulin alone and intravenous immunoglobulin combined with high-dose aspirin in the acute stage of Kawasaki disease: study protocol for a randomized controlled trial.
Kuo HC; Guo MM; Lo MH; Hsieh KS; Huang YH
BMC Pediatr; 2018 Jun; 18(1):200. PubMed ID: 29933749
[TBL] [Abstract][Full Text] [Related]
26. Corticosteroids Added to Initial Intravenous Immunoglobulin Treatment for the Prevention of Coronary Artery Abnormalities in High-Risk Patients With Kawasaki Disease.
Ae R; Abrams JY; Maddox RA; Schonberger LB; Nakamura Y; Kuwabara M; Makino N; Matsubara Y; Kosami K; Sasahara T; Belay ED
J Am Heart Assoc; 2020 Sep; 9(17):e015308. PubMed ID: 32811256
[TBL] [Abstract][Full Text] [Related]
27. Intravenous Immunoglobulin for the Treatment of Kawasaki Disease.
Shulman ST
Pediatr Ann; 2017 Jan; 46(1):e25-e28. PubMed ID: 28079915
[TBL] [Abstract][Full Text] [Related]
28. Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease.
Chan H; Chi H; You H; Wang M; Zhang G; Yang H; Li Q
BMC Pediatr; 2019 May; 19(1):158. PubMed ID: 31101091
[TBL] [Abstract][Full Text] [Related]
29. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome.
Inoue Y; Okada Y; Shinohara M; Kobayashi T; Kobayashi T; Tomomasa T; Takeuchi K; Morikawa A
J Pediatr; 2006 Sep; 149(3):336-341. PubMed ID: 16939743
[TBL] [Abstract][Full Text] [Related]
30. Corticosteroid Therapy Might be Associated with the Development of Coronary Aneurysm in Children with Kawasaki Disease.
Zhao CN; Du ZD; Gao LL
Chin Med J (Engl); 2016 Apr; 129(8):922-8. PubMed ID: 27064036
[TBL] [Abstract][Full Text] [Related]
31. Kawasaki disease: Medical therapies.
Newburger JW
Congenit Heart Dis; 2017 Sep; 12(5):641-643. PubMed ID: 28580631
[TBL] [Abstract][Full Text] [Related]
32. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
Yılmazer MM; Özdemir R; Meşe T; Küçük M; Öner T; Devrim İ; Bayram N; Güven B; Tavlı V
Turk J Pediatr; 2019; 61(5):648-656. PubMed ID: 32104995
[TBL] [Abstract][Full Text] [Related]
33. Effect of different doses of aspirin on the prognosis of Kawasaki disease.
Wang J; Chen H; Shi H; Zhang X; Shao Y; Hang B; Xu Z; Rong X; Chu M; Qiu H
Pediatr Rheumatol Online J; 2020 Jun; 18(1):48. PubMed ID: 32527316
[TBL] [Abstract][Full Text] [Related]
34. Aspirin Dose in Kawasaki Disease: The Ongoing Battle.
Dhanrajani A; Chan M; Pau S; Ellsworth J; Petty R; Guzman J
Arthritis Care Res (Hoboken); 2018 Oct; 70(10):1536-1540. PubMed ID: 29287309
[TBL] [Abstract][Full Text] [Related]
35. A low-frequency IL4R locus variant in Japanese patients with intravenous immunoglobulin therapy-unresponsive Kawasaki disease.
Amano Y; Akazawa Y; Yasuda J; Yoshino K; Kojima K; Kobayashi N; Matsuzaki S; Nagasaki M; Kawai Y; Minegishi N; Ishida N; Motoki N; Hachiya A; Nakazawa Y; Yamamoto M; Koike K; Takeshita T
Pediatr Rheumatol Online J; 2019 Jul; 17(1):34. PubMed ID: 31269967
[TBL] [Abstract][Full Text] [Related]
36. Initial intravenous gammaglobulin treatment failure in Kawasaki disease.
Wallace CA; French JW; Kahn SJ; Sherry DD
Pediatrics; 2000 Jun; 105(6):E78. PubMed ID: 10835091
[TBL] [Abstract][Full Text] [Related]
37. Functional benefits of corticosteroid and IVIG combination therapy in a coronary artery endothelial cell model of Kawasaki disease.
Inoue T; Murakami S; Matsumoto K; Matsuda A
Pediatr Rheumatol Online J; 2020 Oct; 18(1):76. PubMed ID: 33023630
[TBL] [Abstract][Full Text] [Related]
38. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM; Silverman ED; McCrindle BW; Yeung RS
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[TBL] [Abstract][Full Text] [Related]
39. Kawasaki Disease: Beyond IVIG and Aspirin.
Moussa T; Wagner-Weiner L
Pediatr Ann; 2019 Oct; 48(10):e400-e405. PubMed ID: 31609999
[TBL] [Abstract][Full Text] [Related]
40. Kawasaki disease: 40 years after the original report.
Gedalia A
Curr Rheumatol Rep; 2007 Aug; 9(4):336-41. PubMed ID: 17688844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
